Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America
Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.
What LEVI-04 data suggest about the future of disease-modifying osteoarthritis therapies
LEVI-04 Phase II data from Levicept Ltd. signal a shift in osteoarthritis treatment. Discover what this means for disease-modifying therapies.
4Moving Biotech wins FDA Fast Track for 4P004, but can it finally change the knee osteoarthritis treatment playbook?
4Moving Biotech’s 4P004 won FDA Fast Track in knee osteoarthritis. Read what this means for DMOAD development, trial risk, and regulatory strategy.
Does VAS-101 solve a long-standing delivery problem in curcumin-based osteoarthritis treatment?
Vascarta’s VAS-101 showed early knee osteoarthritis pain benefits. Read what the data changes, what remains unclear, and what to watch next.
With AlloJoin Phase 3 in motion, Fosun Kairos takes lead on stem cell therapy rollout in China
ElpasBio partners with Fosun Kairos to commercialize AlloJoin stem cell therapy for KOA in China. Find out what this deal means for the cell therapy market.
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
Why Eli Lilly’s triple agonist may become the first obesity drug with dual indications
Eli Lilly and Company has announced successful topline results from its Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a triple hormone receptor agonist, in adults with obesity and knee osteoarthritis. The once-weekly investigational therapy delivered significant dual benefits: an average weight loss of 28.7 percent and a 75.8 percent reduction in joint pain, measured by […]